Skip to main content
Funded Studies

Farnesoid X Receptor to Reduce Neuroinflammation

Study Rationale:
Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x receptor, protein that regulates metabolism, can reduce inflammation and protect dopamine neurons.

This study hypothesizes that drugs targeting the farnesoid x receptor that are currently in clinical trials for other purposes will reduce neuroinflammation in pre-clinical models of Parkinson's.

Study Design:
We will use two pre-clinical models of PD that both have significant inflammatory components. Existing drugs/compounds that target the farnesoid x receptor will be administered to determine whether they can reduce inflammation and protect dopamine neurons from dying.

Next Steps for Development:
If our experiments are successful, these drugs may progress to clinical trials for Parkinson's more rapidly, as they have been in clinical trials for other conditions.


  • Jason R. Richardson, PhD, MS, DABT

    Rootstown, OH United States

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.